2VERGOULASG, MISERLISG, SOLONAKIF. Combined treatment of hypercholesterolemia of renal transplant allografi recipients with fluvastatin and gemfibrozil. Transpl Int ,2000,13 ( 1 ) :64-67.
7MeaS T, Cimadevilla C,Timsit J, et al. Elevation of CKP induced by ezetimibe in monotherapy, reportnn two eases. Diabetes Metab, 2006,32 (4) : 364 -366.
8Najib J. Fenoflbrate in the treatment of dyslipidemia, a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther,2006,24 ( 12 ) :2022-2050.
3Ballantyne CM,Blazing MA ,King TR,et al. Efficiency and safety of ezetimibe coadministered with simvastatin compared with atorvastatin in adults with hyperclolesterolemia. Amj Cardiol,2004,93 (12):1487～1494
4MartinPD,MitchellPD,Schneck DW.Pharmacodynamic effects and pharmacokinetics of a new HMGCoA reductase inhibitor, rosuvastatin,after morning or evening administration in healthy volunteers [J].Atherosclerosis,2002,53( 3): 154～158
5Bolego C,PoliA,et al .Novel statins :pharmacological and clinical results[J].Cardivasc Drugs Ther ,2002,16(3):251～257
6Farmer JA,Torre-AmioneG.Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Safety,2002,23(3): 197～213
8Brewer HB Jr .Benefit-risk assessment of rosuvastatin 10 to 40 milligrams .Am J Cardiol,2003,92(4B):23K～29K
9Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation[J].Clin, Ther ,2002,24(12):2022～2050
10Bays H ,Stein,EA .Pharmacotherapy for dyslipidaemia-current therapies and future agents[J].Expert Opin Pharmacother,2003,4(11): 1901～ 1938
